Andrea Biondi joins The Lancet Haematology to discuss his work on imatinib as a treatment for paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia.

Prashant Hiwarkar joins The Lancet Haematology to discuss his new paper, an investigation into whether serial faecal PCR monitoring can predict the risk of adenoviraemia and survival outcomes after HSCT.

Lead author Gita Thanarajasingam joins The Lancet Haematology to discuss the new Commission on assessment and adverse event reporting in haematological malignancies.

Jules Heuberger talks about his study on the effectiveness of EPO use by cyclists.

Petra Innerhofer discusses reversal of trauma-induced coagulopathy using first-line coagulation factor concentrates or fresh frozen plasma.

Audrey Bonaventure discusses her CONCORD-2 study, monitoring survival trends of two types of childhood leukaemia in 53 countries between 1995 and 2009.

Jan Beyer discusses the SURPRISE trial of patients developing complications from superficial-vein thrombosis.

Dr Jose Leal discusses a study of the costs related to malignant and non-malignant blood disorders in Europe in 2012.

David Fajgenbaum discusses a literature review to raise awareness of idiopathic multicentric Castleman disease, a poorly understood haematological disorder.

Walter Ageno discusses the use of an algorithm combining limited and whole-leg compression ultrasonography to diagnose deep-vein thrombosis.